Heparin-induced thrombocytopenia type II: successful use of Orgaran (ORG 10172) in intensive care patients.
Burkhard-Meier
U
U
Söhngen
D
D
Schultheiss
H P
HP
Greinacher
A
A
Schwartzkopff
B
B
Vogt
M
M
Heyll
A
A
Schneider
W
W
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004617:Embolism / Q000517:prevention & control*; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced*
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid